Jesse D. Vargas

Jesse D. Vargas

Auto-generated profile, based on publicly available information

Jesse D. Vargas

Cleave Therapeutics Inc., San Francisco, California

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2016 in WIREs Mechanisms of Disease
Verified
Journal Article
Closed access
PDF file
SMSimon Mitchell
Simon Mitchell
JVJesse Vargas
Jesse Vargas
AHAlexander Hoffmann
Alexander Hoffmann

1 January 2012 in Nucleus
Verified
Journal Article
Open access
JVJesse D. Vargas
Jesse D. Vargas
EHEmily M. Hatch
Emily M. Hatch
DADaniel J. Anderson
Daniel J. Anderson
MHMartin W. Hetzer
Martin W. Hetzer
Neoplastic cells are often characterized by specific morphological abnormalities of the nuclear envelope (NE), which have been used for cancer diagnosis for more than a century. The NE is a double ...

20 July 2009 in Journal of Cell Biology
Verified
Journal Article
Open access
DADaniel J. Anderson
Daniel J. Anderson
JVJesse D. Vargas
Jesse D. Vargas
JHJoshua P. Hsiao
Joshua P. Hsiao
MHMartin W. Hetzer
Martin W. Hetzer
Formation of the nuclear envelope (NE) around segregated chromosomes occurs by the reshaping of the endoplasmic reticulum (ER), a reservoir for disassembled nuclear membrane components during mitosis. In this study, we show that inner nuclear membrane proteins such as lamin B receptor (LBR), MAN1, Lap2β, and the trans-membrane nucleoporins Ndc1 and POM121 drive the spreading of ER membranes into the emerging NE via their capacity to bind chromatin in a collaborative manner. Despite their redundant functions, decreasing the levels of any of these trans-membrane proteins by RNAi-mediated knockdown delayed NE formation, whereas increasing the levels of any of them had the opposite effect. Furthermore, acceleration of NE formation interferes with chromosome separation during mitosis, indicating that the time frame over which chromatin becomes membrane enclosed is physiologically relevant and regulated. These data suggest that functionally distinct classes of chromatin-interacting membrane proteins, which are present at nonsaturating levels, collaborate to rapidly reestablish the nuclear compartment at the end of mitosis.

1 October 2014 in Genes & Development
Verified
Journal Article
Open access
PDF file
ACAndrew B. Caldwell
Andrew B. Caldwell
ZCZhang Cheng
Zhang Cheng
JVJesse D. Vargas
Jesse D. Vargas
HBHarry A. Birnbaum
Harry A. Birnbaum
AHAlexander Hoffmann
Alexander Hoffmann
A hallmark of the inflammatory response to pathogen exposure is the production of tumor necrosis factor (TNF) that coordinates innate and adaptive immune responses by functioning in an autocrine or paracrine manner. Numerous molecular mechanisms contributing to TNF production have been identified, but how they function together in macrophages remains unclear. Here, we pursued an iterative systems biology approach to develop a quantitative understanding of the regulatory modules that control TNF mRNA synthesis and processing, mRNA half-life and translation, and protein processing and secretion. By linking the resulting model of TNF production to models of the TLR-, the TNFR-, and the NFκB signaling modules, we were able to study TNF’s functions during the inflammatory response to diverse TLR agonists. Contrary to expectation, we predicted and then experimentally confirmed that in response to lipopolysaccaride, TNF does not have an autocrine function in amplifying the NFκB response, although it plays a potent paracrine role in neighboring cells. However, in response to CpG DNA, autocrine TNF extends the duration of NFκB activity and shapes CpG-induced gene expression programs. Our systems biology approach revealed that network dynamics of MyD88 and TRIF signaling and of cytokine production and response govern the stimulus-specific autocrine and paracrine functions of TNF.

31 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BRBlandine Roux
Blandine Roux
CVCamille Vaganay
Camille Vaganay
JVJesse D. Vargas
Jesse D. Vargas
GAGabriela Alexe
Gabriela Alexe
CBChaima Benaksas
Chaima Benaksas
LBLina Benajiba
Lina Benajiba
The development and survival of cancer cells require adaptive mechanisms to stress. Such adaptations can confer intrinsic vulnerabilities, enabling the selective targeting of cancer cells. Through a pooled in vivo short hairpin RNA (shRNA) screen, we identified the adenosine triphosphatase associated with diverse cellular activities (AAA-ATPase) valosin-containing protein (VCP) as a top stress-related vulnerability in acute myeloid leukemia (AML). We established that AML was the most responsive disease to chemical inhibition of VCP across a panel of 16 cancer types. The sensitivity to VCP inhibition of human AML cell lines, primary patient samples, and syngeneic and xenograft mouse models of AML was validated using VCP-directed shRNAs, overexpression of a dominant-negative VCP mutant, and chemical inhibition. By combining mass spectrometry–based analysis of the VCP interactome and phospho-signaling studies, we determined that VCP is important for ataxia telangiectasia mutated (ATM) kinase activation and subsequent DNA repair through homologous recombination in AML. A second-generation VCP inhibitor, CB-5339, was then developed and characterized. Efficacy and safety of CB-5339 were validated in multiple AML models, including syngeneic and patient-derived xenograft murine models. We further demonstrated that combining DNA-damaging agents, such as anthracyclines, with CB-5339 treatment synergizes to impair leukemic growth in an MLL-AF9–driven AML murine model. These studies support the clinical testing of CB-5339 as a single agent or in combination with standard-of-care DNA-damaging chemotherapy for the treatment of AML.

20 April 2015 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
DODiana R. Ourthiague
Diana R. Ourthiague
HBHarry Birnbaum
Harry Birnbaum
NONiklas Ortenlöf
Niklas Ortenlöf
JVJesse D. Vargas
Jesse D. Vargas
RWRoy Wollman
Roy Wollman
AHAlexander Hoffmann
Alexander Hoffmann
The innate immune response is largely initiated by pathogen-responsive activation of the transcription factor IRF3. Among other target genes, IRF3 controls the expression of IFN-β, which triggers the activation of the transcription factor ISGF3 via the IFNAR. IRF3 and ISGF3 have been reported to control many of the same target genes and together, control the antimicrobial innate-immune program; however, their respective contributions and specificities remain unclear. Here, we used genomic technologies to characterize their specificity in terms of their physical DNA-binding and genetic function. With the use of ChiP-seq and transcriptomic measurements in WT versus ifnar−/− versus ifnar−/−irf3−/− macrophages responding to intracellular dsRNA, we confirmed the known ISGF3 DNA-binding motif and further specified a distinct IRF3 consensus sequence. The functional specificity of IRF3 is particularly pronounced in cytokine/chemokine regulation; yet, even in the control of IFN-β, that specificity is not absolute. By mathematically modeling IFN-β production within an abstracted tissue layer, we find that IRF3 versus ISGF3 specificity may be critical to limiting IFN-β production and ISGF3 activation, temporally and spatially, but that partial overlap in their specificity is tolerable and may enhance the effectiveness of the innate-immune response.